Theravance Biopharma Inc. believes its highly selective 5HT-4 receptor agonist, velusetrag (TD-5108), has potential as a new treatment for gastroparesis – or delayed stomach emptying – on the back on Phase IIb data where only the lowest dose tested reached significance in the primary endpoint.
The company is now preparing to meet regulators to discuss the next phase in its development plan for the product....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?